-
Associations between the meniscal lesion parameters and knee joint structures and symptoms in patients with symptomatic knee osteoarthritis Arthritis Res. Ther. (IF 4.4) Pub Date : 2025-06-03
Kaida Bo, Xin Liu, Yuanyi Zhang, Jianliang Ou, Xu Wang, Maolin Yang, Lianhui Zhao, Zhangwei Wu, Jingfeng Liu, Shuo Yang, Wei Zhang, Lelei Zhang, Zhonglin Xu, Kun Cao, Jun ChangTo investigate cross-sectional associations between meniscal lesion parameters and knee joint structures and symptoms in patients with symptomatic knee osteoarthritis (KOA). A total of 102 subjects with symptomatic KOA were included in this study. Coronal magnetic resonance imaging was used to measure the meniscal parameters including the mean distance from medial to lateral meniscal lesions (Mean(MLD))
-
Artificial intelligence-based Raynaud’s quantification index (ARTIX): an objective mobile-based tool for patient-centered assessment of Raynaud’s phenomenon Arthritis Res. Ther. (IF 4.4) Pub Date : 2025-06-03
Marco Di Battista, Seda Colak, Anna Howard, Francesca Donadoni, Chris Owen-Smith, Andrea Rindone, Stefano Di Donato, Collette Hartley, Lesley-Anne Bissell, Francesco Del GaldoWe aimed to develop an artificial intelligence algorithm able to assess Raynaud’s phenomenon (RP) from mobile phone photography, ensuring as a patient-centered, image-based method for RP quantification. ARTIX (artificial intelligence-based Raynaud’s quantification index) score was developed as a multi-step process of segmentation, decomposition and filters application to mobile phone pictures of the
-
Clinical impact of multiparametric contrast‐enhanced dual‐energy computed tomography in arthritis imaging – a prospective single‐center study Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-06-03
Sevtap Tugce Ulas, Jürgen Mews, Sarah Ohrndorf, Robert Biesen, Katharina Ziegeler, Edgar Wiebe, Fabian Proft, Udo Schneider, Denis Poddubnyy, Torsten DiekhoffObjectivesTo evaluate the influence of contrast‐enhanced dual‐energy CT (CE‐DECT) in detecting and differentiating rheumatic joint diseases of the hand.MethodsIn this prospective study, patients with suspected arthritis of the hand were investigated consecutively alongside the standard clinical procedure. CE‐DECT with sequential rotations was performed in all patients pre and three‐minutes post weight‐adapted
-
Expert Perspective: Diagnosis and Treatment of Castleman Disease Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-06-03
Luke Y.C. Chen, Lu Zhang, David C. Fajgenbaum -
Correspondence to Recurrence Risk in Pediatric Non‐Infectious Uveitis during Adalimumab Tapering: An International Multicenter Retrospective Study Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-06-03
Xiuwen Wang, Aihui Liu, James Cheng Chung Wei, Zhenhua YingClick on the article title to read more.
-
Long-term effects of selexipag in systemic sclerosis-associated digital ulcers: a case control multicentre observational study Rheumatology (IF 4.7) Pub Date : 2025-06-03
Claudia Iannone, Marco Di Battista, M R Pellico, Ilaria Magi, Antonina Minniti, Giuseppe Armentaro, Silvia Cavalli, Manuel Sette, Laura Giudice, Cristina Bochicchio, Alessandra Della Rossa, Antonio G Tavoni, Fabio Cacciapaglia, Stefano Stano, Martina Orlandi, Dilia Giuggioli, Marta Mosca, Roberto Caporali, Nicoletta Del PapaObjectives Digital ulcers (DUs) affect ∼50% of systemic sclerosis (SSc) patients, causing significant pain and functional impairment. Current management involves both systemic and local therapies. However, the burden in terms of pain and quality of life due to refractory DUs still remains heavy. While selexipag is approved for SSc-associated pulmonary arterial hypertension, its potential in treating
-
Safety of biologic therapy in kidney and liver transplant recipients with systemic inflammatory diseases: a real-world study from Israel Rheumatology (IF 4.7) Pub Date : 2025-06-03
Victoria Furer, Omer Kersh, Mark Berman, Ayelet Grupper, Liane Rabinowich, Hagit Peleg, Elisheva Pokroy-Shapira, Ori ElkayamObjectives Safety is a concern for solid-organ transplant (SOT) recipients with systemic inflammatory diseases (SID) treated with biologic therapy. This study evaluated the safety of biologic therapy in SOT recipients with SID. Methods This retrospective study between 2000–2024 included 20 biologic-treated SOT recipients with SID matched to 56 SOT recipients controls without SID not treated with biologic
-
Predictive factors and clinical outcomes of progressive pulmonary fibrosis in anti-threonyl (PL7) positive anti-synthetase syndrome Rheumatology (IF 4.7) Pub Date : 2025-06-03
Xueyan Shan, Zhenguo Huang, Guochun Wang, Yongpeng GeObjectives Patients with anti-threonyl (PL7) positive anti-synthetase syndrome (ASS) exhibit a high prevalence of interstitial lung disease (ILD), which can progress to progressive pulmonary fibrosis (PPF) and increased mortality. This study aims to explore the clinical characteristics, imaging features, and predictive factors for PPF. Methods A retrospective cohort of PL7-ASS patients at a single
-
JAK inhibitors alleviate metabolic dysregulation, inflammation and fibrosis in osteoarthritis: insights from human joint cells and synovium Rheumatology (IF 4.7) Pub Date : 2025-06-03
Geneviève Paulissen, Olivier Malaise, Céline Deroyer, Edith Charlier, Sophie Neuville, Zelda Plener, Thierry Thirion, Christophe Daniel, Clio Ribbens, Dominique de SenyObjectives Osteoarthritis (OA) presents a significant clinical challenge due to its heterogeneous nature, characterized by cartilage degradation, inflammation, and fibrosis. Current treatments offer limited efficacy, highlighting the need for novel therapeutic approaches. Our study aimed to investigate the effects of two JAK inhibitors, tofacitinib and baricitinib, on various hallmarks of OA in human
-
High levels of EPSTI1 enhance IFN-β-mediated HLA-A expression and chemokine secretion in myoblasts in dermatomyositis Rheumatology (IF 4.7) Pub Date : 2025-06-03
Xiaojing Li, Ting Ding, Yizhi Xiao, Junyu Zhou, Ting huang, Shasha Xie, Qiming Meng, Weijia He, Hongling Zhu, Hui LuoObjectives Epithelial-Stromal Interaction 1 (EPSTI1), an interferon-related gene that has emerged as a gene of notable interest, plays a multifaceted role in cellular function and disease processes. However, the precise role of EPSTI1 in the context of dermatomyositis(DM) remains elusive and requires further exploration. Methods To investigate EPSTI1 expression in DM, we analyzed two transcriptome
-
Serum IL-40 is elevated in systemic sclerosis and is linked to disease activity, gastrointestinal involvement, immune regulation and fibrotic processes Arthritis Res. Ther. (IF 4.4) Pub Date : 2025-06-02
Adéla Navrátilová, Sabína Oreská, Hana Wünsch, Klára Mocová, Ondřej Kodet, Marian Rybar, Glenda Alquicer, Aneta Prokopcová, Viktor Bečvář, Radim Bečvář, Aneta Jiránková, Anna Bobrová, Kateřina Bobrová, Karel Pavelka, Jiří Vencovský, Ladislav Šenolt, Lucie Andrés Cerezo, Michal TomčíkInterleukin 40 (IL-40) is a cytokine implicated in malignancies and rheumatic disorders. Its association with fibrotic mediators has been previously described. Since inflammation and fibrosis are hallmarks of systemic sclerosis (SSc), we aimed to analyze the role of IL-40 in SSc. IL-40 levels were analyzed in the serum of 90 SSc patients and 75 healthy controls (HCs). IL-40 expression in dermal biopsies
-
Efferocytosis and its role in rheumatic diseases Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-06-02
Xiaoyu Tang, Yani Peng, Zenan Jiang, Bilian Yu, Daoquan Peng, Xi Xie, Fen Li, Yan GeEfferocytosis, the process through which phagocytes clear apoptotic cells (ACs), has rapidly emerged as an expanding field of research. This multi‐step process involves recognizing, binding, internalizing, and degrading ACs. Efferocytosis clears ACs, preventing their secondary necrosis, generating anti‐inflammatory mediators, and promoting the resolution of inflammation. Appropriate efferocytosis is
-
Lung transplantation outcomes of patients with interstitial pneumonia with autoimmune features: a single center retrospective cohort study Rheumatology (IF 4.7) Pub Date : 2025-06-02
Alec Yu, Hyein Kim, Robert D Levy, Jennifer M Wilson, Darya S Jalaledin, James Choi, John Yee, Charles D Poirier, Sabrina Anh-Tu Hoa, Océane Landon-Cardinal, Kun HuangObjective Interstitial pneumonia with autoimmune features (IPAF) describes patients with interstitial lung disease (ILD) and autoimmune features without meeting criteria for a specific rheumatic disease. No longitudinal data exist on post-transplant outcomes in IPAF patients. We compared baseline demographics, pre-transplant characteristics, and post-transplant outcomes between IPAF and idiopathic
-
Roles of VWA1 and Rac2 in compensatory and decompensatory responses via FGF9/FGFR3 and p38 MAPK signaling pathways in condylar chondrocytes under distinct mechanical stress Arthritis Res. Ther. (IF 4.4) Pub Date : 2025-05-31
Yuqi Liu, Fangwen Jia, Kangya Li, Chao Liang, Yanxi Li, Wei GengFew studies paid attention to compensatory and decompensatory responses of condylar cartilage under different mechanical conditions and the underlying mechanism. Compensatory and decompensatory models were established. In vivo compensatory (0.5 mm occlusal elevation) and decompensatory (1.5 mm elevation) models were established in rats using zirconia occlusal plates. Parallel in vitro models subjected
-
Osteoclast development from peripheral blood monocytes is reduced in patients with radiographic axial spondyloarthritis on biological therapy Arthritis Res. Ther. (IF 4.4) Pub Date : 2025-05-30
Cecilia Engdahl, Malin C. Erlandsson, Magnus Hallström, Anna Deminger, Helena Forsblad-d’EliaRadiographic axial spondyloarthritis (r-axSpA) is a chronic inflammatory disease that primarily affects the axial skeleton and entheses, leading to pathological spinal bone formation and systemic bone loss. Treatments with tumor necrosis factor inhibitors (TNFi) and interleukin-17 inhibitors (IL-17i) have shown efficacy in reducing inflammation and potentially impacting bone remodeling in r-axSpA.
-
Correction to: Impact of incident rheumatoid arthritis on earnings: a nationwide sibling comparison study. Rheumatology (IF 4.7) Pub Date : 2025-06-01
-
Journal Club Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-05-30
Click on the article title to read more.
-
In This Issue Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-05-30
Click on the article title to read more.
-
Issue Information Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-05-30
Click on the article title to read more.
-
Clinical Connections Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-05-30
Click on the article title to read more.
-
Cardiovascular and venous thromboembolic events in systemic sclerosis: epidemiological analysis of the Clinical Practice Research Datalink Rheumatology (IF 4.7) Pub Date : 2025-05-30
John D Pauling, Rachel Charlton, Laura Ross, Neil J McHugh, Anita McGroganObjectives Cardiovascular disease is a leading cause of mortality in systemic sclerosis (SSc). We investigated the association between SSc and the occurrence of both cardiovascular and thromboembolic events using the Clinical Practice Research Datalink (CPRD). Methods A validated case-ascertainment strategy identified SSc patients in the CPRD. A cohort study design examined rates of coronary arterial
-
Enhancing systemic lupus erythematosus treatment outcomes with an early initiation of belimumab: insights from a multicenter retrospective study within the first five years Arthritis Res. Ther. (IF 4.4) Pub Date : 2025-05-29
Kanako Kojima, Kunihiro Ichinose, Masataka Umeda, Toshimasa Shimizu, Shuntaro Sato, Takahisa Suzuki, Yoshikazu Nakashima, Akitomo Okada, Yoshiro Horai, Keita Fujikawa, Toshiyuki Aramaki, Taiichiro Miyashita, Masako Furuyama, Naoki Matsuoka, Atsushi KawakamiThe human monoclonal antibody belimumab (BEL) has emerged as a promising treatment for systemic lupus erythematosus (SLE), particularly for reducing the need for glucocorticoids and minimizing organ damage. The optimal timing of BEL initiation has been unclear; emerging evidence suggests that early intervention with BEL, particularly within the first 5 years of diagnosis, may yield better outcomes
-
Interferon-γ release assay as an emergent powerful biomarker in systemic lupus erythematosus Rheumatology (IF 4.7) Pub Date : 2025-05-29
Yves Renaudineau, Emmanuel Treiner, Fabrice Herin, Stanislas Faguer, Gregory Pugnet, Laurent SaillerObjectives To investigate the ex vivo IFN-γ release assay (IGRA) as a biomarker of SLE activity and disease outcome. Methods This retrospective study, conducted between 2008 and 2024 at a single tertiary care center, included 145 SLE patients at various disease stages. Data were collected on spontaneous IFN-γ levels (IGRA-nil) and on phytohemagglutinin-induced IFN-γ levels (IGRA-PHA, after subtracting
-
An exploratory trial of a single dose of CAM2043 (treprostinil subcutaneous depot) in systemic sclerosis-related Raynaud’s phenomenon Rheumatology (IF 4.7) Pub Date : 2025-05-29
Ariane L Herrick, Andrea Murray, Graham Dinsdale, Joanne Manning, Chukwuma Chukwu, Marcia Alvarez Fernandez, Ulrika Axling, James R Seibold, Fredrik TibergObjectives Our aim was to explore the effect of a single subcutaneous dose of CAM2043, a novel extended-release subcutaneous formulation of treprostinil, on finger temperature in patients with systemic sclerosis (SSc)-related Raynaud’s phenomenon (RP). Methods This was an exploratory, open-label, single-dose Phase 2 trial. Ten female patients (median age 54.0 years) attended on 6 occasions: screening
-
Ankylosed posterior spinal structures: the catalyst for syndesmophytes growth and impaired spinal mobility in axial spondyloarthritis Rheumatology (IF 4.7) Pub Date : 2025-05-29
Simin Liao, Jian Zhu, Liuquan Cheng, Zheng Zhao, Gui Luo, Chuan Song, Jiaxin Zhang, Feng HuangObjective To identify risk factors for spinal structural progression and determine the most significant impact on syndesmophytes growth and impaired spinal mobility in axSpA. Methods Baseline and 2-year follow-up clinical, thoracic and lumbar spine CT data of 94 patients were analyzed. Vertebral syndesmophytes unit (VSU) was defined as syndesmophytes anterior to vertebral body and its intervertebral
-
Insights into Lyme arthritis Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-05-28
Holly WebsterTwo complimentary studies provide a deeper understanding of Lyme disease and the associated chronic complications, such as Lyme arthritis.
-
Changes in Pain Sensitization after DMARD therapy are Associated with Changes in Disease Activity in Established Rheumatoid Arthritis Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-05-28
Burcu Aydemir, Andrew C. Heisler, Lutfiyya N. Muhammad, Jing Song, Alyssa Wohlfahrt, Daniel J. Clauw, Wendy Marder, Marcy B. Bolster, Clifton O. Bingham, Tuhina Neogi, Yvonne C. LeeObjectiveAbnormalities in pain regulatory mechanisms are common in patients with rheumatoid arthritis (RA). We investigated whether pain sensitization changes after treatment with a disease modifying anti‐rheumatic drug (DMARD) and explored associations between changes in pain sensitization and disease activity.MethodsWe included 182 participants with active RA initiating/switching DMARD therapy who
-
The 2024 Vasculitis Foundation Quality Care Summit: Seeking Strategies to Improve Care for All Patients Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-05-28
Jason Springer, Elizabeth Brant, Anisha Dua, Jason Wadler, Dahlia Mak, Peter Merkel, Beth Westbrook, Joyce Kullman, Kevin Byram -
Hospitalised with fever: worthy of serum ferritin. Rheumatology (IF 4.7) Pub Date : 2025-05-28
Ian Harrowell,Randy Q Cron,Athimalaipet V Ramanan -
The safety of low-dose methotrexate for rheumatic diseases: looking beyond blood monitoring. Rheumatology (IF 4.7) Pub Date : 2025-05-28
Sarah L Mackie,Catherine L Hill -
Correction to: Sustained drug-free remission in giant cell arteritis. Rheumatology (IF 4.7) Pub Date : 2025-05-28
-
Immunoadsorption as a novel therapy for refractory idiopathic inflammatory myopathies—a retrospective observational study Rheumatology (IF 4.7) Pub Date : 2025-05-28
Kastriot Kastrati, Thomas Karonitsch, Hanien Rajab, Roman Reindl-Schwaighofer, Farsad Eskandary, Sahra Pajenda, Daniel Mrak, Peter Maximilian Heil, Hans Peter Kiener, Michael Bonelli, Kurt Derfler, Daniel Aletaha, Josef S Smolen, Helga RadnerObjective Idiopathic inflammatory myopathies (IIM) are autoimmune disorders characterised by muscle inflammation, high creatine kinase (CK) levels, and disability. Despite immunomodulating therapies, patients often experience progressive disease, resulting in refractory conditions or dependence on glucocorticoids (GC). This study addresses the efficacy and safety of immunoadsorption (IAS) in refractory
-
Peripheral blood gene expression profiling shows prognostic significance for the course of interstitial lung disease in systemic sclerosis Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-05-27
Shervin Assassi, Christopher P. Denton, Matthias Zwick, Ramona Schmid, Carina Ittrich, Tobias Litzenburger, Sudha VisvanathanObjectiveWe used data from the placebo arm of the SENSCIS trial to determine the prognostic/predictive significance of peripheral blood cell (PBC) transcript modules for the course of forced vital capacity (FVC) in patients with systemic sclerosis‐associated interstitial lung disease (SSc‐ILD) with and without mycophenolate mofetil (MMF) treatment.MethodsPatients had SSc‐ILD with first non‐Raynaud
-
Impact of Interleukin‐1 Blockade on the Development of Macrophage Activation Syndrome in Still's Disease: Incidence and Diagnostic Validity of the EULAR/ACR/PRINTO 2016 MAS Classification Criteria Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-05-27
Remco G.A. Erkens, Greta Rogani, Laura Huber, Anouk Verwoerd, Dieneke Schonenberg‐Meinema, J. Merlijn van den Berg, Wineke Armbrust, G. Elizabeth Legger, Sylvia Kamphuis, Ellen J.H. Schatorjé, Esther P.A.H. Hoppenreijs, Joost F. Swart, Marc H.A. Jansen, Jorg van Loosdregt, Sebastiaan J. VastertObjectiveTo evaluate the applicability of the 2016 EULAR/ACR/PRINTO macrophage activation syndrome (MAS) classification criteria in patients with Still's disease (sJIA‐SD) treated with IL‐1‐targeted therapy and to assess the incidence of MAS in this context.MethodsWe analyzed retrospective and prospective data from Dutch sJIA‐SD patients (diagnosis 2008‐2017, n=54) and data from a nationwide prospective
-
Interleukin-6 receptor blockade leads to low fibrinogen values as part of their effects on the acute phase. Rheumatology (IF 4.7) Pub Date : 2025-05-27
Martin Achleitner,Oliver Tiebel,Nicolai Leuchten,Martin Aringer -
Clinical-imaging characteristics and management of anti-JO-1 and non-JO-1 anti-synthetase syndrome-associated interstitial lung disease Rheumatology (IF 4.7) Pub Date : 2025-05-27
Wanqing Zhou, Ranxun Chen, Xi Chen, Weiwei Xie, Qingqing Xu, Yin Liu, Lulu Chen, Bi Chen, Jinghong DaiObjectives Given a substantial proportion of patients with ASS-ILD (anti-synthetase syndrome-associated interstitial lung disease) develop progressive pulmonary fibrosis (PPF), we aimed to investigate the clinical-radiographic characteristics and treatment in patients with or without anti-Jo-1 antibody. Methods Patients diagnosed with ASS-ILD from two centers were retrospectively reviewed and stratified
-
Risk of heart disease in neonates born to mothers with primary Sjögren’s syndrome: a multicenter retrospective study Rheumatology (IF 4.7) Pub Date : 2025-05-27
Yingbo Zhou, Meilin Shao, Yinzhao Jin, Zhen Tan, Li Wang, Yan Ma, Nan Xiang, Xiang Yuan, Bin Wang, Jie Meng, Xiangliang Xie, Mingtao Zhou, Yunmin Wang, Lin Liu, Xiaomei LiObjective The impact of primary Sjögren’s syndrome (pSS) on adverse pregnancy outcomes remains a debated issue. Research suggests that newborns of mothers with pSS may be at a higher risk of developing heart conditions. This study aimed to examine the relationship between maternal pSS and the risk of cardiac disorders in neonates. Methods A multicentre, retrospective cohort study was conducted with
-
Clinical features, treatment, and outcome of isotretinoin-associated sacroiliitis Arthritis Res. Ther. (IF 4.4) Pub Date : 2025-05-26
Shaoli Zhao, Wei Sun, Liping Peng, Chunjiang WangSacroiliitis is a rare adverse reaction of isotretinoin. However, the data on the clinical features, treatment and outcomes of isotretinoin-associated sacroiliitis are limited. This study was conducted to explore the clinical characteristics of isotretinoin-associated sacroiliitis, providing a basis for diagnosis and treatment. The author retrieved clinical reports of isotretinoin-associated sacroiliitis
-
Functional work disability from the perspectives of persons with systemic lupus erythematosus: a qualitative thematic analysis Arthritis Res. Ther. (IF 4.4) Pub Date : 2025-05-26
Behdin Nowrouzi-Kia, Aaron S. Howe, Anson Li, Jeremy Tan, Natalia Saade-Cleves, Kevon Jules, Malak Sadek, Ali Bani-Fatemi, Antonio Avina-Zubieta, Mary T. Fox, William Shaw, Derek Haaland, Janet Pope, Paul R. Fortin, Kathleen S. Bingham, Christine Peschken, Jennifer Reynolds, Catherine Ivory, Dafna D. Gladman, Murray B. Urowitz, Jorge Sanchez-Guerrero, Lily S. H. Lim, Stephanie Keeling, Patti Katz,Systemic lupus erythematosus (SLE) disease symptoms that can significantly restrict work ability and work participation resulting in reduced mental well-being. This study investigates the significant impact of work participation and disability on the mental wellbeing, health-related quality of life, and disease-related outcomes in individuals with SLE. With the objective of creating an SLE-related
-
Efficacy and safety of epaminurad, a potent hURAT1 inhibitor, in patients with gout: a randomized, placebo-controlled, dose-finding study Arthritis Res. Ther. (IF 4.4) Pub Date : 2025-05-26
Jae-Bum Jun, Hye-Soon Lee, Sang-Hyon Kim, Seung-Geun Lee, Doo-Ho Lim, Jinhyun Kim, Yong-Beom Park, Mie Jin Lim, Seung-Jae Hong, Hyo-Jin Choi, Shin-Seok Lee, Hyun Ah Kim, Jiwon Hwang, Chang-Hee Suh, Seungwoo Han, Jung-Yoon Choe, Wan-Hee Yoo, Jung Soo SongGout is the most common inflammatory arthritis. Current urate-lowering therapies have limitations, such as adverse drug reactions or limited efficacy. Epaminurad is a novel selective human urate transporter 1 (hURAT1) inhibitor that has been shown to reduce serum urate (sUA) levels in healthy volunteers and patients with gout. The aims of the current study were to evaluate the urate-lowering efficacy
-
Efficacy and safety of dotinurad versus febuxostat for the treatment of gout: a randomised, multicentre, double‐blind, phase 3 trial in China Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-05-26
Jia Sun, Yu Wang, Yongjing Cheng, Dongmei Guo, Jiankang Hu, Dongzhou Liu, Zhengnan Gao, Changgui Li, Yibing Lu, Xiaodan Kong, Yu Liu, Zhenyu Jiang, Bin Yi, Hongfeng Zhang, Baijie Xu, Shihao Yu, Rieko Kokan, Kohei Ishikawa, Mikiko Kawakatsu, Zhuoli ZhangObjectivesDotinurad is a selective urate reabsorption inhibitor that reduces serum urate levels. We compared the efficacy and safety of dotinurad with febuxostat in Chinese patients with gout.MethodsThis phase 3, multicentre, randomised, double‐blind, parallel‐group study randomly allocated (1:1) eligible patients with gout to receive oral dotinurad or febuxostat. The primary endpoint was the responder
-
Comparative Cardiovascular Safety of NSAID versus Colchicine Use When Initiating Urate‐Lowering Therapy Among Patients with Gout: Target Trial Emulations Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-05-26
Chio Yokose, Natalie McCormick, Na Lu, Bohang Jiang, Kiara Tan, Saiajay Chigurupati, Sharan Rai, Greg Challener, J. Antonio Aviña‐Zubieta, Edoardo Cipolletta, Abhishek Abhishek, Angelo Gaffo, James L. Januzzi, Yuqing Zhang, Hyon K. ChoiObjectiveAmong patients with gout, NSAIDs are commonly used despite scarce safety data in this specific population. Therefore, we quantified the comparative cardiovascular safety of NSAIDs versus colchicine among patients with gout starting allopurinol.MethodsWe conducted a sequential, propensity score‐matched, new‐user comparative effectiveness study using the target trial emulation framework to compare
-
Machine Learning Analysis of Whole‐Blood Transcriptomics Data in Rheumatoid Arthritis Patients Treated with Adalimumab Identifies Predictive Biomarkers of Response Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-05-26
Chuan Fu Yap, Nisha Nair, Ann W Morgan, John D Isaacs, Anthony G Wilson, Kimme Hyrich, Guillermo Barturen, María Riva‐Torrubia, Marta Gut, Ivo Gut, Marta E. Alarcón Riquelme, Anne Barton, Darren PlantObjectivesTumor necrosis factor inhibitors (TNFi) have significantly improved rheumatoid arthritis (RA) management, yet variability in patient response remains a substantial challenge, with approximately 40% of patients discontinuing TNFi due to non‐response or adverse effects. This study aimed to identify biomarkers predictive of adalimumab treatment response using whole blood transcriptomics, leveraging
-
Performance of the new PREVENT Score for indicating subclinical atherosclerosis in rheumatoid arthritis Rheumatology (IF 4.7) Pub Date : 2025-05-24
J Alex B Gibbons, Joan M Bathon, Jon T GilesObjectives Patients with rheumatoid arthritis (RA) are at increased risk of atherosclerotic cardiovascular disease (ASCVD), yet traditional 10-year CVD risk calculators—such as the 2013 Pooled Cohort Equations (PCE)—underperform in RA. Our objective was to determine the performance of the PCE vs the updated PREVENT algorithm in indicating presence of subclinical coronary and carotid atherosclerosis
-
Baricitinib for Takayasu arteritis refractory to TNF-α inhibitors: a multi-centre, single-arm trial Rheumatology (IF 4.7) Pub Date : 2025-05-24
Jiachen Li, Weiyi Xia, Huijuan Ji, Xiaoxin Gong, Qi Dong, Yanan Wu, Longjun Wang, Meixia Peng, Jingxuan Liu, Ke Ma, Qi Yu, Xinglei Cui, Yuanyuan Luo, Wenhua Zhu, Shumin Zhang, Shi Chen, Yuhui Li, Zhanguo Li, Tian LiuObjective This study aimed to assess the efficacy and safety of baricitinib in Takayasu arteritis (TAK) refractory to TNF-α inhibitors. Methods We conducted a multicentre, single-arm trial between February 2021 and August 2023. Patients with TAK unresponsive to at least 6 months of TNF-α inhibitors were treated with baricitinib 4 mg daily for up to 48 weeks, while continuing of immunosuppressants and
-
Myositis-specific autoantibody subtypes are associated with response to Janus kinase inhibitors in patients with juvenile dermatomyositis Rheumatology (IF 4.7) Pub Date : 2025-05-24
Brigitte Bader-Meunier, Thomas R J Moreau, Florence Aeschlimann, François-Jérome Authier, Jean Luc Charuel, Fabienne Jouen, Olivier Boyer, Christine Bodemer, Anne Welfringer-Morin, Vincent Bondet, Benjamin Fournier, Pierre Quartier, Marie-Louise Frémond, Anne-Perrine Foray, Carlos Sanchez, Darragh Duffy, Cyril Gitiaux, Mathieu P RoderoObjectives To evaluate the efficacy and safety of Janus kinase inhibitors (JAKi) in a monocentric series of patients with JDM and to identify factors associated with the achievement of clinically inactive disease (CID). Methods Single-centre retrospective study of 39 JDM patients treated with JAKi for at least 6 months. The proportion of patients achieving CID within 6 months after initiation of JAKi
-
Pregnancy outcomes after maternal and paternal anti-IL-1 treatment exposure in cryopyrin-associated periodic syndromes (CAPS) Rheumatology (IF 4.7) Pub Date : 2025-05-24
Özlem Satirer, Jörg Henes, Melanie Henes, Susanne M Benseler, Jasmin B Kuemmerle-DeschnerObjectives To determine the effect of paternal and maternal anti-IL-1 treatment exposures on pregnancies and neonatal outcomes in CAPS. Methods A single-centre study consecutive adult CAPS patients and their partners was performed between January 2012 and July 2024. All were screened for pregnancies and anti-IL-1 exposure before conception and/or during pregnancy; teratogenic co-therapies resulted
-
Association between steatotic liver disease and risk of incident systemic sclerosis: a nationwide cohort study Rheumatology (IF 4.7) Pub Date : 2025-05-24
Oh Chan Kwon, Kyu-Na Lee, Kyungdo HanObjective Antinuclear antibody (ANA) positivity has been observed in patients with steatotic liver disease (SLD); however, the link between SLD and ANA-positive connective tissue diseases remains unexplored. We aimed to evaluate the association between SLD and risk of systemic sclerosis (SSc), a representative ANA-positive connective tissue disease. Methods A longitudinal population-based cohort study
-
Bifidobacterium ameliorates lupus nephritis and modulates aberrant differentiation of lymphocyte subsets Rheumatology (IF 4.7) Pub Date : 2025-05-24
Lihua Wu, Zhirong Guan, Xiaoyu Zhang, Yanan Liu, Shuhong Chi, Xiangguo Duan, Chunxia SuObjectives The gut microbiota is crucial in the progression of lupus nephritis (LN), and probiotics have emerged as a potential therapeutic approach. This study investigates the role of Bifidobacterium in LN pathogenesis and its effects on immune cell populations. Methods Clinical samples were collected from 61 systemic lupus erythematosus (SLE) patients, and flow cytometry was used to analyze changes
-
Reply to comments on “Association of thigh intramuscular fat infiltration with incident knee and hip osteoarthritis: a longitudinal cohort study” Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-05-23
Qianlin Weng, Ting Jiang, Tuo Yang, Chao ZengClick on the article title to read more.
-
Editorial: The environment and Systemic Autoimmune Rheumatic Diseases (SARDS): What do we know after more than 15 years of research? Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-05-23
Jaime E. Hart, Karen H. CostenbaderClick on the article title to read more.
-
Reply to: Comments on Peripheral Biomarker Signatures in Rheumatoid Arthritis‐Associated Interstitial Lung Disease. Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-05-23
Austin M. Wheeler, Ted R. Mikuls, Bryant R. EnglandClick on the article title to read more.
-
Association of physicians' Big Five personality traits with shared decision-making in patients with systemic lupus erythematosus Rheumatology (IF 4.7) Pub Date : 2025-05-23
Shigemi Morishita, Ken-ei Sada, Masataka Kudo, Naofumi Dobashi, Sho Sasaki, Ryusuke Yoshimi, Natsuki Sakurai, Chiharu Hidekawa, Yasuhiro Shimojima, Dai Kishida, Takanori Ichikawa, Yoshia Miyawaki, Keigo Hayashi, Kenta Shidahara, Yuichi Ishikawa, Nao Oguro, Nobuyuki Yajima, Noriaki Kurita, Narufumi SuganumaObjectives Recent European League Against Rheumatism guidelines highlight the importance of shared decision-making (SDM) in systemic lupus erythematosus (SLE) treatment. This study investigated the relationship between physicians' personality traits and patient-rated SDM. Methods Using baseline data from the Trust Measurements for Physicians and Patients with SLE (TRUM2-SLE) study, physicians' personality
-
Glucocorticoids versus glucocorticoids plus cyclophosphamide in eosinophilic granulomatosis with polyangiitis without poor-prognosis factors: a target trial emulation study Rheumatology (IF 4.7) Pub Date : 2025-05-23
Boris Sorin, Matthias Papo, Renato Alberto Sinico, Vítor Silvestre Teixeira, Nils Venhoff, Maria-Letizia Urban, Michele Iudici, Juliane Mahrhold, Francesco Locatelli, Giulia Cassone, Franco Schiavon, Benjamin Seeliger, Thomas Neumann, Claudia Feder, Claus Kroegel, Matthieu Groh, Chiara Marvisi, Maxime Samson, Thomas Barba, David Jayne, Arianna Troilo, Jens Thiel, Bernhard Hellmich, Sara Monti, CarlomaurizioObjectives Current recommendations suggest treating eosinophilic granulomatosis with polyangiitis (EGPA) without severe manifestations with glucocorticoids (GCs) and EGPA with severe manifestations with GCs plus cyclophosphamide (CYC) regardless of poor-prognostic factors. However, GCs plus CYC and GCs alone have never been compared in EGPA without poor-prognosis factors assessed by the 1996 Five Factor
-
Upadacitinib in the treatment of Takayasu Arteritis: a case report on new perspectives on targeted immunomodulation. Rheumatology (IF 4.7) Pub Date : 2025-05-23
Alexander Pfeil,Wiebke Schulze,Ulf Teichgräber,Tobias Hoffmann,Niklas Eckardt,Christian Geis,Falk Gühne,Martin Freesmeyer,Gunter Wolf,Albrecht Günther -
Artificial intelligence-driven categorization of rheumatological disease subgroups. Rheumatology (IF 4.7) Pub Date : 2025-05-23
Keerthi Talari,Vinod Ravindran -
Characterization of fibroblast-like synoviocytes from the synovial fluid of patients affected by juvenile idiopathic arthritis Rheumatology (IF 4.7) Pub Date : 2025-05-23
Simone Pelassa, Federica Raggi, Ignazia Prigione, Francesca Ridella, Angelo Ravelli, Marco Gattorno, Alessandro Consolaro, Maria Carla BoscoObjectives To characterize some phenotypic and functional aspects of fibroblast-like synoviocytes isolated from the synovial fluid (SF-FLS) of patients affected by Juvenile Idiopathic Arthritis (JIA) with active disease and to compare SF-FLS characteristics to those reported in the literature for FLS of the synovial membrane (SM) in adult rheumatic patients. Methods FLS were isolated from the SF of
-
CRTAC1: a novel indicator of lung involvement in systemic sclerosis Rheumatology (IF 4.7) Pub Date : 2025-05-23
Aneta Prokopcova, Sabina Oreska, Hana Wunsch, Jiri Baloun, Radim Becvar, Ladislav Senolt, Michal TomcikObjectives Interstitial lung disease (ILD) is the most frequent cause of mortality in patients with systemic sclerosis (SSc). Cartilage acidic protein-1 (CRTAC1), secreted by alveolar type-2 epithelial cells, is a potential biomarker of lung health. This study explores CRTAC1's role in SSc, focusing on pulmonary involvement. Methods We collected plasma samples from 76 SSc patients (65 females, limited
-
The lack of association between cumulative methotrexate dose and liver fibrosis in psoriatic arthritis: a cohort study Rheumatology (IF 4.7) Pub Date : 2025-05-23
Fadi Kharouf, Pankti Mehta, Virginia Carrizo Abarza, Shangyi Gao, Daniel Pereira, Dafna D Gladman, Denis Poddubnyy, Vinod ChandranObjectives Evidence for the association between methotrexate use and liver fibrosis in psoriatic arthritis (PsA) remains inconclusive. We aimed to explore the frequency of liver fibrosis in PsA and identify associated factors including cumulative methotrexate dose and metabolic features. Methods We analyzed data from a prospective observational PsA cohort. We calculated the Aspartate Aminotransferase
-
Anti-mitochondrial antibodies as markers of disease activity in childhood-onset systemic lupus erythematosus: a longitudinal cohort study Rheumatology (IF 4.7) Pub Date : 2025-05-23
Marina Barguil Macêdo, M Javad Wahadat, Albin Björk, Sylvia Kamphuis, Marjan A Versnel, Christian LoodObjectives Mitochondria are prominent antigenic sources, capable of triggering interferon-induced inflammatory pathways in systemic lupus erythematosus (SLE). Recent studies suggest presence of anti-mitochondria autoantibodies (AMA) in lupus nephritis patients with adult-onset SLE. Whether AMA reflect disease activity in childhood-onset SLE (cSLE) remains unexplored. Here, we present inaugural data